Vapotherm Inc

Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. Its products include Precision Flow, Precision Flow Heliox, Oxygen Assist Module, Nitric Oxidie Disposable Patient Circuit, Tracheostomy Adapter, and Aerogen Adapter. The company was founded by William F. Niland, Jun Cortez, and William Cirksena in 1998 and is headquartered in Exeter, NH.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Vapotherm (VAPO) to Report a Decline in Earnings: What to Look Out for

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 via webcast. Vapotherm is sch

Vapotherm to Participate in the Canaccord Genuity 41st Annual Growth Conference

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Monday, August 9, 2021. Vapotherm's management team will host a

Vapotherm to Report Second Quarter 2021 Financial Results

Vapotherm has benefited from the pandemic, at least sales saw a boost, but earnings did not. 2021 saw a solid start to the year, but the guidance for the remainder of the year is not inspiring, both in terms of sales and losses.

Vapotherm: Hardly Breathing Room

EXETER, N.H,--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be hosting their first investor day on Wednesday, June 23, 2021 beginning at 10:00AM ET. The event will be held in person at the co

Vapotherm to Host First Investor Day

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the William Blair 41st Annual Growth Stock Conference on Tuesday, June 1, 2021 via webcast. Vapotherm is schedu

Vapotherm to Participate in the William Blair 41st Annual Growth Stock Conference

Vapotherm, Inc. (VAPO) CEO Joe Army on Q1 2021 Results - Earnings Call Transcript

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in the Bank of America Securities 2021 Health Care Conference on Wednesday, May 12, 2021 via webcast. Vapotherm wi

Vapotherm to Participate in the Bank of America Securities 2021 Health Care Conference

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced first quarter 2021 financial results. First Quarter 2021 Summary Revenue for the first quarter of 2021 was $32.3 million, representing a 69% increase over the pri

Vapotherm Reports First Quarter 2021 Financial Results

Will Vapotherm (VAPO) Report Negative Earnings Next Week? What You Should Know

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2021 after the close of trading on Wednesday, May 5, 2021. Vapotherm's management team will host a

Vapotherm to Report First Quarter 2021 Financial Results

Vapotherm, Inc.'s (VAPO) CEO Joseph Army on Q4 2020 Results - Earnings Call Transcript

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat Patients of all ages suffering from respiratory distress, today announced fourth quarter and fiscal year 2020 financial results. Fourth Quarter 2020 Summary Net revenue for the fourth quarter of 2020 was $40.9 million, representing a 2

Vapotherm Reports Fourth Quarter and Fiscal Year 2020 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be participating in a Fireside Chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on We

Vapotherm to Participate in Fireside Chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the fourth quarter and fiscal year 2020 after the close of trading on Wednesday, February 24, 2021. Vapotherm's manage

Vapotherm to Report Fourth Quarter and Fiscal Year 2020 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced certain preliminary unaudited fourth quarter and full year 2020 revenue results. Preliminary revenue for the fourth quarter of 2020 is expected to be approximate

Vapotherm Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the 23rd Annual ICR/Westwicke Conference on Thursday, January 14, 2021 via webcast. Vapotherm is scheduled to pres

Vapotherm to Present at the 23rd Annual ICR/Westwicke Conference

EXETER, N.H.--(BUSINESS WIRE)---- $VAPO--Vapotherm, Inc. (NYSE:VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® systems, has been awarded the prestigious American Association for Respiratory Care Zenith Award. The American Association for Respiratory Care (AARC) presents the award to only six out of more than 300 manufacturers, supply organizations, and supply companies based on

Vapotherm Wins Prestigious Zenith Award from American Association for Respiratory Care for Support of Respiratory Therapists

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced an update to its fourth quarter and fiscal year 2020 revenue guidance given on November 4, 2020. Fourth Quarter and Fiscal Year 2020 Outlook For fourth quarter 2

Vapotherm Updates Its Fourth Quarter and Fiscal Year 2020 Outlook

Vapotherm's Hi-VNI technology is more comfortable and safer than current technologies used to treat patients with respiratory distress. The company has seen meaningful sales increases over the past two quarters due to COVID-19 as many medical associations are recommending its technology over the current SOC NIPPV.

Vapotherm: The Game Has Completely Changed

Vapotherm, Inc. (VAPO) CEO Joe Army on Q3 2020 Results - Earnings Call Transcript

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced third quarter 2020 financial results. Third Quarter 2020 Summary Revenue for the third quarter of 2020 was $30.6 million as compared to $10.8 million for the third quarter of 2019, r

Vapotherm Reports Third Quarter 2020 Financial Results

Vapotherm (VAPO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

MENLO PARK, Calif.--(BUSINESS WIRE)--CIBC Innovation Banking is pleased to announce a US$52 million growth capital financing with Exeter-based Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress. Vapotherm will use the funding to repay its existing revolving loan facility and term loan facility. “V

CIBC Innovation Banking Provides Global Medical Technology Company Vapotherm Inc. With a US$52 Million Growth Financing

EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary high velocity therapy, which is used to treat patients of all ages suffering from respiratory distress, today announced the appointment of Donald Spence to the Company's Board of Directors. Mr. Spence will serve as a member and chair of the Compensation Committee, and as a member of the Audit Committe

News for Vapotherm Inc Stock (VAPO)